Status:
COMPLETED
Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer
Lead Sponsor:
Institut Cancerologie de l'Ouest
Collaborating Sponsors:
Poitiers University Hospital
IASON Gmbh, Feldkirchner strasse 4, 8054 Graz-Seiesberg AUSTRIA
Conditions:
Prostate Adenocarcinoma
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
With functional imaging development, it becomes possible to increase radiation dose to radioresistant areas (located inside tumor volume) using radiotherapy dose-painting. This strategy is particularl...
Eligibility Criteria
Inclusion
- histologically proven prostate adenocarcinoma
- Absence of metastases (lymph node or bone)
- One or more tumor nodules seen on MRI and PET Choline.
- Intermediate Risk : Gleason 7 and PSA (prostate specific antigen)\<20 ng / ml, T \<T2c or Gleason 6 and PSA 10-20 ng / ml, T \<T2c
- No concomitant hormonal treatment. (NB: the introduction of hormone therapy during radiotherapy before the second 18F-MISO is a criterion to study exit)
- Indication of radiotherapy up to a total dose\> 70 Gy and 2 Gy/day fractions
- Signed Informed consent
- Social Insurance
Exclusion
- Age \< 18 years old
- Patient protected by law
Key Trial Info
Start Date :
June 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2015
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01898065
Start Date
June 1 2012
End Date
February 1 2015
Last Update
November 9 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Poitiers
Poitiers, France, 86000
2
ICO Rene Gauducheau
Saint-Herblain, France, 44805